DoctoRx
Special situations, growth at reasonable price, value, micro-cap

Supernus Finding Success, Looks Undervalued

Background: A spin-off from Shire plc (NASDAQ:SHPG), Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a niche pharmaceutical company. To date, it has not just one but two areas of specialization: it operates in the neurology space with a neuro-psych pipeline, and at least so far, it only develops controlled-release products.

It released Q2 results Tuesday, which showed rapid growth of its two marketed products. It also provided additional positive news and a positive outlook. Trading well below its highs in both time and price, and now trading at an extraordinarily low price:sales ratio, SUPN now appears to be on the bargain counter. As disclosed in my article published Monday, I have written about SUPN before on Seeking...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details